Published in J Rheumatol on November 01, 2003
Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes (2009) 1.43
Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol (2008) 1.34
Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res (2014) 1.03
The use and abuse of commercial kits used to detect autoantibodies. Arthritis Res Ther (2003) 0.94
Computer-assisted pattern recognition of autoantibody results. Clin Diagn Lab Immunol (2005) 0.84
Missing links in high quality diagnostics of inflammatory systemic rheumatic diseases: It is all about the patient! Auto Immun Highlights (2012) 0.83
Is closer linkage between systemic lupus erythematosus and anti-double-stranded DNA antibodies a desirable and attainable goal? Arthritis Res Ther (2005) 0.81
The spectrum of anti-chromatin/nucleosome autoantibodies: independent and interdependent biomarkers of disease. J Immunol Res (2014) 0.79
Interpretation of ANA indirect immunofluorescence test outside the darkroom using NOVA view compared to manual microscopy. J Immunol Res (2014) 0.79
Plasminogen activator inhibitor-1 polymorphisms (-844 G>A and HindIII C>G) in systemic lupus erythematosus: association with clinical variables. Clin Exp Med (2010) 0.78
Antinuclear antibody testing - misunderstood or misbegotten? Nat Rev Rheumatol (2017) 0.76
The Use of Poly-L-Lysine as a Capture Agent to Enhance the Detection of Antinuclear Antibodies by ELISA. PLoS One (2016) 0.75
Genomics and proteomics: Applications in autoimmune diseases. Pharmgenomics Pers Med (2009) 0.75
Next-Generation Autoantibody Testing by Combination of Screening and Confirmation-the CytoBead® Technology. Clin Rev Allergy Immunol (2017) 0.75
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum (2010) 18.82
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis (2010) 12.12
Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet (2002) 7.90
Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses (2002) 7.03
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum (2011) 6.28
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum (2004) 6.22
Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther (2005) 4.86
Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med (2002) 4.54
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 4.15
International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis (2013) 3.99
Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med (2003) 3.89
Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther (2008) 3.44
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum (2006) 3.29
Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis (2013) 3.25
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med (2008) 2.99
Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med (2008) 2.97
Very recent onset arthritis--clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol (2002) 2.97
Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J Clin Microbiol (2004) 2.94
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis (2010) 2.91
Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med (2005) 2.89
Determination of mean recency period for estimation of HIV type 1 Incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res Hum Retroviruses (2010) 2.86
Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest (2002) 2.85
Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum (2005) 2.76
Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. J Exp Med (2004) 2.73
Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum (2002) 2.52
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis (2014) 2.40
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum (2005) 2.32
Guidelines for performing single-platform absolute CD4+ T-cell determinations with CD45 gating for persons infected with human immunodeficiency virus. Centers for Disease Control and Prevention. MMWR Recomm Rep (2003) 2.28
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis (2014) 2.24
Sonographic joint assessment in rheumatoid arthritis: associations with clinical joint assessment during a state of remission. Arthritis Rheum (2013) 2.22
Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther (2006) 2.18
Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev (2003) 2.14
Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J Hepatol (2006) 2.11
Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum (2012) 2.10
The influence of pregnancy on the development of autoimmunity in chronic lymphocytic leukemia. Leuk Lymphoma (2006) 2.07
Development and validation of modified disease activity scores in rheumatoid arthritis: superior correlation with magnetic resonance imaging-detected synovitis and radiographic progression. Arthritis Rheumatol (2014) 2.06
EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis (2013) 2.05
Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum (2009) 2.04
The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis (2012) 2.03
TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J Exp Med (2008) 1.99
Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. Ann Rheum Dis (2011) 1.97
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum (2010) 1.94
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2011) 1.93
Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov (2012) 1.91
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum (2002) 1.91
Increased natural CD4+CD25+ regulatory T cells and their suppressor activity do not contribute to mortality in murine polymicrobial sepsis. J Immunol (2006) 1.86
A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford) (2009) 1.82
Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol (2005) 1.81
Focal cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke (2004) 1.81
Early structural changes in cartilage and bone are required for the attachment and invasion of inflamed synovial tissue during destructive inflammatory arthritis. Ann Rheum Dis (2012) 1.81
Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum (2007) 1.80
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis (2012) 1.78
Diagnosis of prostate cancer using differentially expressed genes in stroma. Cancer Res (2011) 1.78
The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am (2006) 1.77
Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation (2005) 1.75
Kidney preservation by bone marrow cell transplantation in hereditary nephropathy. Kidney Int (2011) 1.72
Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum (2002) 1.72
Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res (2003) 1.72
Phenotypic and functional analysis of CD4+ CD25- Foxp3+ T cells in patients with systemic lupus erythematosus. J Immunol (2009) 1.71
Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol (2005) 1.70
Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2002) 1.70
Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum (2007) 1.68
The use of canines in the detection of human cancers. J Altern Complement Med (2008) 1.68
HIV type 1 incidence estimates by detection of recent infection from a cross-sectional sampling of injection drug users in Bangkok: use of the IgG capture BED enzyme immunoassay. AIDS Res Hum Retroviruses (2003) 1.68
The IL-4 receptor alpha-chain-binding cytokines, IL-4 and IL-13, induce forkhead box P3-expressing CD25+CD4+ regulatory T cells from CD25-CD4+ precursors. J Immunol (2005) 1.66
Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. J Clin Virol (2011) 1.66
Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. Arthritis Rheum (2005) 1.64
Diagnostic accuracy for lupus and other systemic autoimmune diseases in the community setting. Arch Intern Med (2004) 1.63
Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc Natl Acad Sci U S A (2010) 1.63
TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci U S A (2007) 1.61
Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol (2003) 1.61
Mechanisms of Disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol (2005) 1.55
Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis (2010) 1.54
Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum (2004) 1.53
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. Ann Rheum Dis (2010) 1.53
The evolution of human anti-double-stranded DNA autoantibodies. Proc Natl Acad Sci U S A (2005) 1.53
Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol (2011) 1.52
Applying public health strategies to primary immunodeficiency diseases: a potential approach to genetic disorders. MMWR Recomm Rep (2004) 1.52
Pristane-induced autoimmunity in germ-free mice. Clin Immunol (2005) 1.51
Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum (2004) 1.51
A novel type I IFN-producing cell subset in murine lupus. J Immunol (2008) 1.50
Estrogen-dependent and C-C chemokine receptor-2-dependent pathways determine osteoclast behavior in osteoporosis. Nat Med (2009) 1.50
Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol (2003) 1.50
Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Rheum (2009) 1.49
Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. Ann Rheum Dis (2009) 1.48
Type I interferon modulates monocyte recruitment and maturation in chronic inflammation. Am J Pathol (2009) 1.47
Application of laboratory methods for estimation of HIV-1 incidence. Indian J Med Res (2005) 1.47
Microglial activation and matrix protease generation during focal cerebral ischemia. Stroke (2007) 1.47
Prostate brachytherapy seed migration and dosimetry: analysis of stranded sources and other potential predictive factors. Brachytherapy (2004) 1.47
Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl-pentadecane (pristane). Am J Pathol (2006) 1.47
Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum (2002) 1.46
A new hypothesis of the possible mechanisms of gender differences in systemic lupus erythematosus. Clin Exp Rheumatol (2010) 1.45